Phase II trial of menogaril in advanced colorectal cancer

✍ Scribed by Eduard E. Holdener; Wim W. Bokkel Huinink; Genevieve Decoster; Christian Ludwig; Georgette Renard; Herbert M. Pinedo

• Publisher: Springer US
• Year: 1988
• Tongue: English
• Weight: 262 KB
• Volume: 6
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/bf00175404

✦ Synopsis

Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were achieved. Myelosuppression, only leukopenia, was usually of mild-moderate degree and occurred in 63~ of the patients. Twenty-seven percent of the patients experienced severe leukopenia. Local erythema and phlebitis were frequently observed and were severe in 13070 of the patients. Nausea/vomiting (66%) and alopecia (50%) were of mild-moderate degree.

This study suggests that menogaril at these doses and schedule had no activity in advanced colorectal cancer.